One of the major challenges in using pancreatic cancer patient–derived organoids (PDOs)
in precision oncology is the time from biopsy to functional characterization. This is …

Tumor purity, or the relative contribution of tumor cells out of all cells in a pathological
specimen, influences mutation identification and clinical interpretation of cancer panel next …

PURPOSE ERBB2 amplification (human epidermal growth factor receptor 2 positivity
[HER2+]) in metastatic colorectal cancer (mCRC) has important therapeutic implications that …

Amplicon-based next generation sequencing (NGS) approaches have been preferentially
adopted by the clinical laboratories on the basis of a short turnaround time (TAT) and small …

Background Adoption of high-throughput, gene panel-based, next-generation sequencing
(NGS) into routine cancer care is widely supported, but hampered by concerns about cost …

Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals
with breast cancer. Due to their low abundance in the circulation, robust CTC expansion …

Genetic alterations are the starting point leading to numerous changes in clinical and
pathologic features (phenotypes) of individual cancers; however, their inter‐relationships in …

Background Sensitive and reliable molecular diagnostics is needed to guide therapeutic
decisions for cancer patients. Although less material becomes available for testing, genetic …

Estrogen receptor‐positive breast cancer is a highly prevalent but heterogeneous disease
among women. Advanced molecular stratification is required to enable individually most …

The molecular classification of breast cancer plays a pivotal role in developing personalized
treatment strategies, with the aim of improving therapeutic outcomes. Despite significant …